Four years of low dose enzalutamide for metastatic castration-resistant prostate cancer
Language English Country Czech Republic Media print
Document type Case Reports, Journal Article
PubMed
33657823
DOI
10.48095/ccko202169
PII: 125896
Knihovny.cz E-resources
- Keywords
- castration-resistant, enzalutamide, prostate cancer, prostatic neoplasms, reduced-dose drug use, treatment efficacy, treatment outcomes,
- MeSH
- Benzamides administration & dosage MeSH
- Phenylthiohydantoin administration & dosage MeSH
- Kallikreins blood MeSH
- Humans MeSH
- Prostatic Neoplasms, Castration-Resistant blood drug therapy pathology radiotherapy MeSH
- Nitriles administration & dosage MeSH
- Prostatectomy MeSH
- Prostate-Specific Antigen blood MeSH
- Antineoplastic Agents administration & dosage MeSH
- Aged, 80 and over MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Benzamides MeSH
- enzalutamide MeSH Browser
- Phenylthiohydantoin MeSH
- Kallikreins MeSH
- KLK3 protein, human MeSH Browser
- Nitriles MeSH
- Prostate-Specific Antigen MeSH
- Antineoplastic Agents MeSH
BACKGROUND: The management of metastatic castration-resistant prostate cancer involves second-generation antiandrogen therapy, including enzalutamide. The recommended dose of 160mg/day is sometimes difficult to use in elderly patients because of the burden of comorbidities. The usefulness of a low effective dose remains unclear. METHODS: We report the first ever patient, now aged 87 years, who had progressing prostate cancer and was treated at 25% of the recommended dose for over 4 years. RESULTS: The most striking observation is that nothing extraordinary happened. The disease responded without dramatic toxicities. His follow-up has been serene on both aspects of prostate cancer and general health. CONCLUSION: Cautious dosage can have a long-lasting favorable impact in the elderly patient.
References provided by Crossref.org
